~~<i id='CEAF073C72'><strike id='CEAF073C72'><tt id='CEAF073C72'><pre id='CEAF073C72'></pre></tt></strike></i>~~

Home» Wikipedia» Wikipedia

Wikipedia

author：explore 2025-09-27 12:01:40 Page View：3

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Attacks on the drug industry will lead to fewer breakthroughs
Next article： 23andMe had bad news about my health. I wish a person had delivered it

explore

Hollywood unions extend contract negotiations for actors

1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

In search for therapies for solid tumors, companies turn to claudin

MollyFergusonforSTATOnTargetisarecurringfeaturefromSTATthatdivesdeepintothemostpromisingdrugtargetsi

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

Microsoft strikes partnership with Duke Health to advance health AI

LIONELBONAVENTURE/AFPviaGettyImagesOnTuesday,DukeHealthandMicrosoftannouncedafive-yearpartnershiptha